Basic Clinical Radiobiology 2017

• FLAME-trial Randomized phase III trial

• Standard arm: 77 Gy/2.2 Gy (35 fr) to the prostate • Experimental arm: additional integrated boost to macroscopically visible tumor, delineated based on 2 different imaging techniques, to a maximal total dose of 95 Gy (35 fr of 2.7 Gy) – Primary endpoint • To decrease the 5-year biochemical relapse rate with at least 10%